2,5-DIBROMO-6-METHYLPYRIDINE | CAS:39919-65-8

We serve 2,5-DIBROMO-6-METHYLPYRIDINE CAS:39919-65-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,5-DIBROMO-6-METHYLPYRIDINE

Chemical Name:2,5-DIBROMO-6-METHYLPYRIDINE
CAS.NO:39919-65-8
Synonyms:2,5-DIBROMO-6-METHYLPYRIDINE
3,6-dibromo-2-methylpyridine
2,5-Dibromo-6-methylpyridine
3,6-Dibromo-2-picoline
 
Physical and Chemical Properties:
Density 1.9±0.1 g/cm3
Boiling Point 243.9±35.0 °C at 760 mmHg
Melting Point 0°C
Molecular Formula C6H5Br2N
Molecular Weight 250.919
Flash Point 101.3±25.9 °C
 
Specification:
Appearance:Redish solid 
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2,5-DIBROMO-6-METHYLPYRIDINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,6-Dibromo-2-picoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-DIBROMO-6-METHYLPYRIDINE Use and application,2,5-DIBROMO-6-METHYLPYRIDINE technical grade,usp/ep/jp grade.


Related News: API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.2-(5-Mercaptotetrazole-1-yl)ethanol manufacturer API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.(1R,3S,4R,5R)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol supplier In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.1-PBFR vendor In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.“We believe such actions are our last resort,” the Hospital Authority Employees Alliance, a union that formed during the city’s antigovernment protest movement, wrote in a statement.